anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: The self-treatment with a foam roller is a popular form of myofascial release, although the underlying mechanisms, particularly on pain sensitivity, remain unclear. It is hypothesized that the hypoalgesic local effects are probably due to changes in fascial and muscle tissue, whereas remote effects may be influenced by central endogenous pain modulation. This systematic review aimed to quantify the difference between local and remote hypoalgesic effects of the foam rolling intervention.
METHOD: A systematic search was conducted in the databases Pubmed, Cochrane Library, Web of Science, and CINAHL. Published randomized controlled trials and non-randomized controlled trials investigating the effects of foam rolling on Pressure Pain Thresholds (PPTs) in healthy individuals and patients with musculoskeletal pain were included. Quality assessment and evidence synthesis were performed according to Cochrane Handbook recommendations. A meta-analysis was performed using standardized mean differences and 95% CIs.
RESULTS: Local PPTs changed after rolling in a pre-post comparison with a small effect size: SMD = -0.42 (95 % CI = -0.57 to -0.26); I2 = 1 %. Remote PPTs also changed after rolling in a pre-post comparison with a small effect size: SMD = -0.47 (95 % CI = -0.80 to -0.14); I2 = 0 %. Foam rolling showed no effect on local PPTs when compared with a control group: SMD = 0.10 (95 % CI = -0.19 to 0.39); I2 = 0 %.
CONCLUSION: No consistent effects of foam rolling on PPTs were demonstrated in healthy individuals.
This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
A device 1 used in conjunction with a valved holding chamber or spacer, 2, and a metered dose inhaler (MDI) 3, capable of recording and improving the delivery of medicine into a patients airway. The device comprises a flow passage forming sealed connections with the MDI outlet and the spacer inlet. The device may further comprise a pressure sensor to detect dispending of medication from the MDI or into the spacer, or the rate and volume of air flow during use. A timer may record the start or duration of dispensation. Agitation of the device may be measured and timed. Feedback to the user may be visual or audible, may consist of LEDs 12 and may be configured to indicate device condition, medication type or dosage, inhalation rate or adherence to optimal inhalation rate. The device may comprise data processing and storage means capable of connecting to other devices.
The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
The present invention provides anti-tumor peptides of formula I, A-B-N(CH3)-CHD-CH(OCH3)-CH2CO-Pro-Pro-K, and the acid salts thereof. A is an amino acid residue of the formula (CH3)2N-CHX-CO, wherein X is a normal or branched alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. D is a normal or branched C3-C4-alkyl group. K is a t-butoxy group or a substituted amino group. An additional embodiment of the present invention is a method for treating a malignancy in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound or compounds of formula I in a pharmaceutically acceptable composition.
In a 6 week clinical trial, 270 steroid naive patients with symptomatic asthma being treated with as-needed beta-agonist bronchodilators, were randomized to receive either 40 mcg twice daily of QVAR, 80 mcg twice daily of QVAR, or placebo. Both doses of QVAR were effective in improving asthma control with significantly greater improvements in FEV1, AM PEF, and asthma symptoms than with placebo. Shown below is the change from baseline in AM PEF during this trial.

In a 6-week clinical trial, 256 patients with symptomatic asthma being treated with as-needed beta-agonist bronchodilators, were randomized to receive either 160 mcg twice daily of QVAR (delivered as either 40 mcg/actuation or 80 mcg/actuation) or placebo. Treatment with QVAR significantly improved asthma control, as assessed by FEV1, AM PEF, and asthma symptoms, when compared to treatment with placebo. Comparable improvement in AM PEF was seen for patients receiving 160 mcg twice daily QVAR from the 40 mcg and 80 mcg strength products.
The invention aims to provide a medical assistance device, an operation method for the medical assistance device, and a medical assistance system. In a display screen of a plurality of items of the medical information, the items can be temporarily set based on the reference to non-display items by a simple operation. An item name display region (41) where item names of a plurality of items included in the medical information of a patient are displayed and a content display region (42) where a graph (G) for each item is displayed are provided on a display screen (15) of a medical assistance client. On the display screen (15), a display/non-display setting of the graph (G) for each item is possible in the content display region (42) by a first operation including a mouse click operation. The graph (G3) of a non-display setting item can be temporarily displayed by a mouse-over operation not including the click operation. The mouse-over operation is an operation of just overlapping a pointer (36) on the item name display region (41).
An article of manufacture for providing a CO2 monitoring smart facemask assembly according to the present invention includes_a CO2 sensor component having a CO2 sensor, a serial data connection, and a power connection, a set of connecting wires, and_a controller unit coupled to the CO2 sensor component by the set of connecting wires. The controller unit includes a programmable microcontroller, the programmable microcontroller receives a measure of a current CO2 value from the CO2 sensor component, a battery, one or more visual alarm devices; and_an auditory alarm device and an alarm reset button 207. The microcontroller activates the one or more visual alarm devices and the auditory alarm devices when the current CO2 value is greater than a pre-defined threshold. This warning will ensure safety of the user and an option to shut the alarm off, thereby after the warning has been acknowledged. The one or more visual alarm devices include one or more LEDs and a display device. The display device shows an alpha-numeric representation of the current CO2 value measured by the CO2 sensor component.
G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues.

Diagnostic enteral radiopaque agents have few known pharmacological effects. Diatrizoate meglumine and diatrizoate sodium exert a mild laxative effect attributable to their high osmolarity.

Diatrizoate meglumine and diatrizoate sodium are sparingly absorbed from the intact gastrointestinal tract, and therefore permit gastrointestinal opacification and delineation after oral or rectal administration. Oral administration is used for radiographic evaluation of the esophagus, stomach and proximal small intestine. Rectal administration is used for examination of the colon; however, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution of the medium. Enough absorption from the gastrointestinal tract to permit incidental visualization of the urinary tract has been reported; this should also be considered when thyroid testing is being contemplated, since iodine-mediated thyrotropic effects may occur (see PRECAUTIONS).
The invention discloses traditional Chinese medicine for treating acute purulent tenosynovitis. The traditional Chinese medicine comprises Emei angiopteris, carduus crispus, calamus tetradactylus, Areca catechu, Ficus lacor Buch.-Ham., Laporteacuspidata (Wedd.) Friis, Japanese pagodatree resin, Piper sarmentosum leaf, Polypodium nipponicum Mett, Berchemia sinica, Desmos chinensis root, Evodia trichotoma leaf, Ardisia maculosa Mez, Delphinium bonvalotii Franch., Schefflera delavayi (Franch.), uncaria root, Alpinia pumila Hook.f., Cirsium vlassovianum Fisch.ex DC.and Rauvolfia verticillata (Lour.) Baill.. The traditional Chinese medicine made of purely natural Chinese herbal medicine materials is capable of treating both the symptoms and root causes, definite in curative effect, free of toxic and side effects and less prone to relapse.
According to the International Society of Lymphology, lymphoedema needs to be treated with Decongestive Lymphatic Therapy (Consensus Document ISL 2013). This is a two-stage treatment programme. During the first or intensive phase, lymphoedema has to be maximally reduced. This phase consists of skin care, manual lymph drainage (MLD), multi-layer bandaging and exercise therapy. The second or maintenance phase aims to conserve and optimise the results obtained in the first phase. It consists of skin care, compression by a low-stretch elastic sleeve, exercises and lymph drainage. Skin care, multi-layer bandaging, elastic sleeve and exercises are treatment modalities that (after instructing the patient) can be performed by the patient herself. MLD has to be applied by a physical therapist and hence entails a big financial cost for the patient and the Health Care (Kärki et al 2009). The effectiveness of MLD applied during the intensive phase has been investigated by 5 randomised controlled trials, but there is conflicting evidence. So, further investigation is warranted to determine the relative benefit of MLD. The effectiveness of MLD applied during the maintenance phase has never been investigated (Devoogdt et al 2010, Oremus et al 2012, Huang et al 2013, Ezzo et al 2015).

A possible explanation why MLD is not obviously proven to be effective, is that MLD is applied in an inefficient way: during MLD, hand manoeuvres are applied on all lymph nodes and lymphatics that may be anatomically present. After axillary dissection and/ or radiotherapy (for the treatment of breast cancer), the lymphatic system is damaged: lymph nodes are removed and often fibrosis of the superficial lymphatic system occurs. As a result, rerouting of the lymphatic drainage occurs. Rerouting is patient-specific, consequently, it is possible that the traditional MLD needs be abandoned and a tailored approach needs to be established. Lymphofluoroscopy can aid to apply a more efficient MLD. During lymphofluoroscopy, a fluorescent substance is injected subcutaneously in the hand and it visualizes the transport of lymph from the hand up to the axilla and it demonstrates alternative pathways towards other lymph nodes.

A second explanation why the traditional method of MLD is not proven to be effective, is that research has shown that MLD with high pressure (vs low pressure) is more effective to improve lymph transport, as well as gliding (vs no gliding). During the new method of MLD (or fluoroscopy-guided MLD), the therapist only performs hand movements on functional lymphatics and lymph nodes. In addition, the hand movements are applied with higher pressure and lymph transport through the lymph collaterals is stimulated by applying strikes across the skin.

Therefore, the main scientific objective entails examining the effectiveness of fluoroscopy-guided MLD versus traditional MLD versus placebo MLD, applied as part of the intensive and maintenance phase of Decongestive Lymphatic Therapy, for the treatment of BCRL
The prevalence of gastric cancer is high in Asia, especially in Korea and Japan. In Korea, the detection rate of EGC has increased with mass screening for the prevention of gastric cancer-related death. EGC is defined as mucosal or submucosal cancer, regardless of regional lymph node metastasis. The presence of lymph node metastasis has been reported to range from 2% to 18%. For this reason, radical gastrectomy with lymph node dissection was considered as the only curative treatment. In EGC patients, surgical outcome demonstrated excellent 5-year survival rate above 90%.

In 2000, EGC subgroups with negligible risk of lymph node metastasis were proposed on the basis of large scale retrospective data. Thereafter, the result was adopted as expanded criteria for endoscopic resection of EGC. ESD is useful technique to dissect the tumor along the submucosal layer using various endoscopic knives. Compared to endoscopic mucosal resection (EMR), ESD achieved a higher complete resection rate and a lower local tumor recurrence rate.

Although curative resection is pathologically achieved by ESD, post-resection surveillance is needed to confirm the presence of nodal metastasis. Recently, several studies reported that 5-year overall and disease-specific survival rate were highly favorable in EGC patients who underwent curative ESD. However, there is no comparative study about long-term outcomes after ESD and gastrectomy. Therefore, this protocol aims to evaluate overall survival rate, tumor recurrence, development of metachronous cancers between ESD and surgery groups.
The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system. Furthermore, the invention relates to a method of providing a titratable amount of therapeutic agent to a patient using the transdermal delivery system of the invention.
The present invention discloses a copper replenisher of slow release control type copper, and a preparation method and a purpose of the copper replenisher. The copper replenisher is zeolite containing active copper, and the content of copper in the zeolite is 1.5% to 10% according to the percentage by weight. In the preparation method, zeolite containing active copper is prepared by the procedures of the adsorption and the ion exchange reaction between a copper salt and natural artificially synthesized zeolite, filtering, drying and pulverizing. The preparation method has the advantages of simple technological process, low production cost and easy popularization and implementation. Because carrier zeolite has the characteristics of good biocompatibility and gastrointestinal tract mucosa compatibility, regular intercommunicating pore canal structure and cage space, high surface activity, large specific surface area, etc., copper carried by the carrier zeolite has a slow release control function, and the absorption and the utilization rate of copper is greatly raised. The slow release control type copper prepared by the present invention can be used as a feed additive applied to copper replenishment for fowls, aquatic livestock, cattle, sheep, etc., and can be also used for preparing human oral taking copper replenishment health products or medicines for treating human diseases by administration of remedial copper. The slow release control type copper has wide application range.
Although acute upper limb ischemia (AULI) is less prevalent than lower acute limb ischemia, AULI may lead to severe morbidity if not well-treated. To manage AULI appropriately, evaluation of the etiologies, risk factors, and revascularization is of importance. Here we present a case of recurrent AULI and its appropriate diagnostic and management approaches. A 27-year-old male with a chief complaint of pain and numbness in his left arm for one week. He had a history of AULI seven months before and was treated by percutaneous intra-arterial thrombolysis at left brachial and radial arteries with residual non-occlusive thrombus. Duplex ultrasound (DUS) and CT angiography revealed a new soft thrombus with occlusion at the left subclavian artery. Evaluation of comorbid risk factors and source of thrombus was performed. The patient underwent pharmacomechanical thrombectomy and angioplasty procedure. The diagnosis of AULI was established based on pain and numbness in the left arm, and the finding of soft thrombus and occlusion of the left subclavian artery on DUS and CT angiography evaluation. Although various workups have been carried out to determine the etiology of AULI in this patient, the definite cause remains unknown. In addition, pharamcomecanical thrombectomy and angioplasty were performed as the appropriate revascularization methods in this condition. Recurrent AULI is a rare vascular phenomenon leading to disabling morbidities and fatal consequences if not treated properly. Further evaluation of etiology and risk factors for recurrent AULI is mandatory for appropriate management besides revascularization.
Patients with baseline AST or ALT >2.5 x ULN or bilirubin >1.5 x ULN experienced greater toxicity than patients with baseline AST or ALT ≤2.5 x ULN or bilirubin ≤1.5 x ULN when treated with IXEMPRA at 40 mg/m 2 in combination with capecitabine or as single agent in breast cancer studies. 

In combination with capecitabine, the overall frequency of grade 3/4 adverse reactions, febrile neutropenia, serious adverse reactions, and toxicity-related deaths was increased oin patients with hepatic impairment. IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity- and neutropenia-related death [see Boxed Warning, Contraindications ( 4), and Warnings and Precautions ( 5.2)]. 

With IXEMPRA single agent therapy, grade 4 neutropenia, febrile neutropenia, and serious adverse reatcitons were increased in patients with hepatic impairment [see Warnings and Precautions ( 5.2) and Adverse Reactions (6.1). Reduce the dose IXEMPRA based in the degree of hepatic impairment. Avoid use in patients with AST or ALT >10 x ULN or bilirubin >3 x ULN [see Dosage and Administration ( 2.4)]
BACKGROUND: Recurrent depressive disorder (RDD) is mainly manifested as a low mood, negative and pessimistic mood, and often presents suicidal tendencies when severe. This study reports on a patient with RDD who experienced rat poison poisoning occurring tongue biting. The patient's psychiatric symptoms improved after receiving emergency management and subsequent combined medical care.
CASE PRESENTATION: The patient was a 51-year-old female with RDD complicated with rat poison poisoning. Tongue bite occurred on the third day of hospitalization. She received emergency treatment. Depression, anxiety and suicide risk assessment, safety management and caregiver-health education were conducted on the day of admission and before discharge. At the follow-up after discharge, the risk of suicide was reduced.
CONCLUSIONS: Suicide in patients with RDD is characterized by repetition and complexity. The occurrence of clinical cases involving tongue bite after gastric lavage is rare. Suicide assessment and emergency management play an auxiliary role in the treatment of patients with recurrent depressive disorder.
In this study the efficacy of an intramuscular formulation of toltrazuril combined with gleptoferron for the control of porcine cystoisosporosis caused by Cystoisospora suis was investigated. The study was carried out on three Belgian farms with a confirmed history of C. suis infections. As none of the farms implemented a standardized toltrazuril treatment regimen for their piglets, the presence of resistant C. suis strains seems improbable. In total 90 litters, representing 1249 piglets, were included in the study and randomly allocated to either the treatment or control group. Piglets in the treatment group received a single intramuscular injection, containing 45 mg toltrazuril and 200 mg gleptoferron, between 1 and 3 days of age. Piglets in the control group received a single injection with only 200 mg gleptoferron. The effect of treatment on oocyst excretion, expressed in oocysts per gram of feces (OPG), average daily weight gain (ADG) and mortality was determined both pre- and post-weaning. A significant decrease in OPG as well as a decrease in the number of litters (pre-weaning) and pens (post-weaning) that tested positive for cystoisosporosis, was observed in the treated animals compared to the controls. Furthermore, treatment resulted in an increased ADG during the period from day 1 to day 21 (p-value: 0.03881). There was no significant difference in mortality observed between the treatment group to the control group (p-value: 0.2167). To our knowledge, this is the first report on the effect of toltrazuril on oocyst excretion after weaning. This finding highlights the potential long-term benefits of the treatment beyond the initial administration.